UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Synergistic effect between EGF and TGF-β1 in inducing oncogenic properties of intestinal epithelial cells

Oncogene, 2008-04, Vol.27 (18), p.2626-2634

2008

Volltextzugriff (PDF)

A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage

European journal of cancer (1990), 2022-10, Vol.174, p.S92-S93

2022

Volltextzugriff (PDF)

Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

Annals of oncology, 2016-10, Vol.27, p.vi228-vi228

2016

Volltextzugriff (PDF)

Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

Annals of oncology, 2016-10, Vol.27, p.vi117-vi117

2016

Volltextzugriff (PDF)

The Role of Phosphatidylinositol 3-Kinase, Rho Family GTPases, and STAT3 in Ros-induced Cell Transformation

The Journal of biological chemistry, 2002-03, Vol.277 (13), p.11107-11115

2002

Volltextzugriff (PDF)

Synergistic effect between EGF and TGF-b1 in inducing oncogenic properties of intestinal epithelial cells

Oncogene, 2008-04, Vol.27 (18), p.2626-2634

2008

Volltextzugriff (PDF)

Synergistic effect between EGF and TGF-[beta]1 in inducing oncogenic properties of intestinal epithelial cells

Oncogene, 2008-04, Vol.27 (18), p.2626-2634

2008

Volltextzugriff (PDF)

Matrix-independent Activation of Phosphatidylinositol 3-Kinase, Stat3, and Cyclin A-associated Cdk2 Is Essential for Anchorage-independent Growth of v-Ros-transformed Chicken Embryo Fibroblasts

The Journal of biological chemistry, 2003-05, Vol.278 (21), p.18798-18810

2003

Volltextzugriff (PDF)

Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells

Oncogene, 2008-04, Vol.27 (18), p.2626

2008

Volltextzugriff (PDF)

Shelley and the dramatic form

UttamSingh, S

1959

Volltextzugriff (PDF)

Shelley and the dramatic form

Uttamsingh, S

1959

Volltextzugriff (PDF)

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-12, Vol.23 (24), p.7490-7497

2017

Volltextzugriff (PDF)

Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib

Drug metabolism and disposition, 2016-10, Vol.44 (10), p.1584-1597

2016

Volltextzugriff (PDF)

A First-in-Human Phase 1 Dose Escalation and Expansion Study of the Oral CARD11-BCL10-MALT1 Signaling Pathway Inhibitor XL114 in Patients with Non-Hodgkin's Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.12055-12056

2022

Volltextzugriff (PDF)

Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib

Drug metabolism and disposition, 2005-11, Vol.33 (11), p.1723-1728

2005

Volltextzugriff (PDF)

Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer

Breast cancer research and treatment, 2020-11, Vol.184 (1), p.53-62

2020

Volltextzugriff (PDF)

A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3176-TPS3176

2022

Volltextzugriff (PDF)

Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine

The Journal of pharmacology and experimental therapeutics, 2015-07, Vol.354 (1), p.43-54

2015

Volltextzugriff (PDF)

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301)

Gynecologic oncology, 2022-08, Vol.166, p.S158

2022

Volltextzugriff (PDF)

Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer

Clinical cancer research, 2020-10, Vol.26 (20), p.5348-5357

2020

Volltextzugriff (PDF)

Evidence-Based Reasoning in Intelligence Analysis: Structured Methodology and System

Computing in science & engineering, 2018-11, Vol.20 (6), p.9-21

2018

Volltextzugriff (PDF)

A declarative approach to composing web services in dynamic environments

Decision Support Systems, 2006, Vol.41 (2), p.325-357

2006

Volltextzugriff (PDF)

Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development

The Journal of pharmacology and experimental therapeutics, 2017-08, Vol.362 (2), p.359-367

2017

Volltextzugriff (PDF)

P.666 Pharmacokinetic and safety profile CTP-692 (deuterated D-serine) following administration of single and multiple ascending doses in healthy volunteers

European neuropsychopharmacology, 2019-12, Vol.29, p.S450-S451

2019

Volltextzugriff (PDF)

Selective deuteration of bupropion slows epimerization and reduces metabolism

Bioorganic & medicinal chemistry letters, 2022-11, Vol.76, p.129009-129009, Article 129009

2022

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(58)
Dissertationen
(5)

Sprache

Englisch
(63)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Synergistic effect between EGF and TGF-β1 in inducing oncogenic properties of intestinal epithelial cells

A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage

Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

The Role of Phosphatidylinositol 3-Kinase, Rho Family GTPases, and STAT3 in Ros-induced Cell Transformation

Synergistic effect between EGF and TGF-b1 in inducing oncogenic properties of intestinal epithelial cells

Synergistic effect between EGF and TGF-[beta]1 in inducing oncogenic properties of intestinal epithelial cells

Matrix-independent Activation of Phosphatidylinositol 3-Kinase, Stat3, and Cyclin A-associated Cdk2 Is Essential for Anchorage-independent Growth of v-Ros-transformed Chicken Embryo Fibroblasts

Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells

Shelley and the dramatic form

Shelley and the dramatic form

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors

Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib

A First-in-Human Phase 1 Dose Escalation and Expansion Study of the Oral CARD11-BCL10-MALT1 Signaling Pathway Inhibitor XL114 in Patients with Non-Hodgkin's Lymphoma

Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib

Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer

A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors

Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301)

Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer

Evidence-Based Reasoning in Intelligence Analysis: Structured Methodology and System

A declarative approach to composing web services in dynamic environments

Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development

P.666 Pharmacokinetic and safety profile CTP-692 (deuterated D-serine) following administration of single and multiple ascending doses in healthy volunteers

Selective deuteration of bupropion slows epimerization and reduces metabolism

Suchergebnisse filtern